Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.
2.

Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison.

el-Yazigi A, Chaleby K.

Psychopharmacology (Berl). 1988;95(1):63-7. Review.

PMID:
3133701
3.

Doxepin concentrations in plasma and cerebrospinal fluid.

Schomburg R, Remane D, Fassbender K, Maurer HH, Spiegel J.

J Neural Transm (Vienna). 2011 Apr;118(4):641-5. doi: 10.1007/s00702-011-0613-x. Epub 2011 Feb 25.

PMID:
21350940
4.

Prediction of steady-state plasma levels of doxepin and imipramine from single dose levels in depressed outpatients.

Hrdina PD, Bakish D, Swenson S, Lapierre YD.

J Psychiatry Neurosci. 1991 Mar;16(1):25-9.

5.

Plasma levels of tricyclic antidepressants and clinical efficacy: review of the literature -- part II.

Risch SC, Huey LY, Janowsky DS.

J Clin Psychiatry. 1979 Feb;40(2):58-69.

PMID:
581671
6.

Early individualization of tricyclic antidepressant dosing using a Bayesian pharmacokinetic model.

Kehoe WA, Harralson AF, Kwentus JA, Jacisin JJ, Sheffel WB, Hetnal MJ.

DICP. 1991 Dec;25(12):1368-73.

PMID:
1815435
7.

Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach.

Meyer-Barner M, Meineke I, Schreeb KH, Gleiter CH.

Eur J Clin Pharmacol. 2002 Jul;58(4):253-7. Epub 2002 Jun 7.

PMID:
12136371
8.

Fatal doxepin intoxication--suicide or slow gradual intoxication?

Neukamm MA, Vogt S, Hermanns-Clausen M, Naue J, Thierauf A, Auwärter V.

Forensic Sci Int. 2013 Apr 10;227(1-3):82-4. doi: 10.1016/j.forsciint.2012.08.050. Epub 2012 Sep 19.

PMID:
22999230
9.

Absolute bioavailability and stereoselective pharmacokinetics of doxepin.

Yan JH, Hubbard JW, McKay G, Korchinski ED, Midha KK.

Xenobiotica. 2002 Jul;32(7):615-23.

PMID:
12162857
10.

Plasma and erythrocyte levels of tricyclic antidepressants in depressed patients.

Linnoila M, Dorrity F Jr, Jobson K.

Am J Psychiatry. 1978 May;135(5):557-61.

PMID:
347952
11.

Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression.

Szymura-Oleksiak J, Wyska E, Wasieczko A.

Psychopharmacology (Berl). 2001 Feb;154(1):38-42.

PMID:
11292004
12.

The effect of sertraline on the pharmacokinetics of desipramine and imipramine.

Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ.

Clin Pharmacol Ther. 1997 Aug;62(2):145-56.

PMID:
9284850
13.

Bioavailability investigation of two different oral formulations of doxepin.

Geister U, Gaupp M, Arnold P, Schaarschmidt D, Doser K, Renner J.

Arzneimittelforschung. 2001;51(3):189-96.

PMID:
11304934
14.

Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse.

Rao ML, Deister A, Laux G, Staberock U, Höflich G, Möller HJ.

Pharmacopsychiatry. 1996 May;29(3):97-102.

PMID:
8738313
15.

Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.

Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E.

Br J Clin Pharmacol. 1997 Mar;43(3):315-8.

16.

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction.

Bergstrom RF, Peyton AL, Lemberger L.

Clin Pharmacol Ther. 1992 Mar;51(3):239-48.

PMID:
1544284
17.

Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?

Birkenhäger TK, van den Broek WW, Moleman P, Vulto AG, Bruijn JA.

Psychopharmacology (Berl). 2005 Sep;181(3):595-9. Epub 2005 Oct 12.

PMID:
16133127
18.

[Tricyclic antidepressants dosage and depressed elderly inpatients: a retrospective pharmaco-epidemiologic study].

Ballon N, Siobud-Dorocant E, Even C, Slama F, Dardennes R.

Encephale. 2001 Jul-Aug;27(4):373-6. French.

PMID:
11686060
19.

Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression.

Pinder RM, Brogden RN, Speight TM, Avery GS.

Drugs. 1977 Mar;13(3):161-218. Review.

PMID:
321205
20.

Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets.

Kirchheiner J, Henckel HB, Franke L, Meineke I, Tzvetkov M, Uebelhack R, Roots I, Brockmöller J.

Pharmacogenet Genomics. 2005 Aug;15(8):579-87.

PMID:
16007002

Supplemental Content

Support Center